POZ Community Forums

Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: Jim Allen on August 12, 2020, 12:27:25 am

Title: FDA Approves Dovato as HIV Switch Option
Post by: Jim Allen on August 12, 2020, 12:27:25 am
 8)

https://www.poz.com/article/fda-approves-dovato-hiv-switch-option

The single-tablet regimen is now approved for previously treated people with an undetectable viral load.

Title: Re: FDA Approves Dovato as HIV Switch Option
Post by: Almost2late on October 02, 2021, 05:13:32 pm
The Dovato combo is holding strong after 3 years.. this is great news.

Quote
Long-Term Data Show Dolutegravir/Lamivudine Non-Inferiority in Efficacy Versus TAF-Based Regimens in HIV

Three-year results from the TANGO study presented at the IDWeek 2021 showed that the 2-drug regimen of dolutegravir/lamivudine (Dovato, GlaxoSmithKline) demonstrated non-inferior efficacy and a high barrier to resistance compared to continuation of tenofovir alafenamide fumarate (TAF)-based regimens of at least 3 drugs in virologically suppressed adults living with HIV-1 who had not experienced prior virologic failure, according to a press release...

https://www.pharmacytimes.com/view/long-term-data-show-dolutegravir-lamivudine-non-inferiority-in-efficacy-versus-taf-based-regimens-in-hiv